REGN-COV2 combines 2 virus-neutralizing monoclonal antibodies that are used against SARS-CoV-2: casirivimab and imdevimab (CAS-IMD).


The CADTH Technology Review evaluated a published interim analysis of a randomized controlled trial of 2 different doses of CAS-IMD in 275 ambulatory adult patients with confirmed SARS-CoV-2 infection.

Link to Report

Casirivimab-Imdevimab for COVID-19: Evidence Review and Appraisal

Provide Feedback

Was this site helpful?

If you couldn’t find what you are looking for, please submit a request.